CAPR catalysts and FDA events, page 2.
Updated Snapshot 20261116T222116ZBuilt
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on CAPR PDUFA dates and upcoming catalysts. This page continues the list.
Past catalysts and FDA decisions (continued)
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| March 4, 2025 | deramiocel (CAP-1002) | CAPR | NDA/BLA accepted | rare diseases, today | Completed | SEC Form 8-K |
| January 2, 2025 | deramiocel (CAP-1002) | CAPR | NDA/BLA submission | diagnosed with Duchenne muscular dystrophy | Completed | SEC Form 8-K |
| Dec 2024Month disclosed | deramiocel (CAP-1002) | CAPR | NDA/BLA accepted | — | Completed | SEC Form 10-Q |
| November 13, 2024 | — | CAPR | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| late 2024Half-year disclosed | deramiocel (CAP-1002) | CAPR | NDA/BLA submission | — | Scheduled | SEC 8-K Exhibit 99.1 |
Every catalyst is quoted from CAPR’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.